XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Balance at beginning of period at Dec. 31, 2021 $ 1 $ 792,971 $ (224) $ (595,407) $ 197,341
Balance at beginning of period (in shares) at Dec. 31, 2021 61,228,446        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units   49     49
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) 509,037        
Unrealized gain (loss) on marketable securities     (748)   (748)
Stock-based compensation expense   2,346     2,346
Net loss       (18,789) (18,789)
Balance at end of period at Mar. 31, 2022 $ 1 795,366 (972) (614,196) 180,199
Balance at end of period (in shares) at Mar. 31, 2022 61,737,483        
Balance at beginning of period at Dec. 31, 2021 $ 1 792,971 (224) (595,407) 197,341
Balance at beginning of period (in shares) at Dec. 31, 2021 61,228,446        
Increase (Decrease) in Stockholders' Equity          
Net loss         (59,273)
Balance at end of period at Sep. 30, 2022 $ 1 875,982 (1,465) (654,680) 219,838
Balance at end of period (in shares) at Sep. 30, 2022 66,679,641        
Balance at beginning of period at Mar. 31, 2022 $ 1 795,366 (972) (614,196) 180,199
Balance at beginning of period (in shares) at Mar. 31, 2022 61,737,483        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units   88     88
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) 91,388        
Issuance of common stock under at-the-market sales agreement, net of offering costs   72,659     72,659
Issuance of common stock under at-the-market sales agreement, net of offering costs (in shares) 4,838,709        
Unrealized gain (loss) on marketable securities     (354)   (354)
Stock-based compensation expense   3,692     3,692
Net loss       (20,532) (20,532)
Balance at end of period at Jun. 30, 2022 $ 1 871,805 (1,326) (634,728) 235,752
Balance at end of period (in shares) at Jun. 30, 2022 66,667,580        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units   (11)     (11)
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) 12,061        
Unrealized gain (loss) on marketable securities     (139)   (139)
Stock-based compensation expense   4,188     4,188
Net loss       (19,952) (19,952)
Balance at end of period at Sep. 30, 2022 $ 1 875,982 (1,465) (654,680) 219,838
Balance at end of period (in shares) at Sep. 30, 2022 66,679,641        
Balance at beginning of period at Dec. 31, 2022 $ 1 880,832 (897) (682,315) $ 197,621
Balance at beginning of period (in shares) at Dec. 31, 2022 66,688,647       66,688,647
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) 517,378        
Unrealized gain (loss) on marketable securities     543   $ 543
Stock-based compensation expense   6,806     6,806
Net loss       (28,160) (28,160)
Balance at end of period at Mar. 31, 2023 $ 1 887,638 (354) (710,475) 176,810
Balance at end of period (in shares) at Mar. 31, 2023 67,206,025        
Balance at beginning of period at Dec. 31, 2022 $ 1 880,832 (897) (682,315) $ 197,621
Balance at beginning of period (in shares) at Dec. 31, 2022 66,688,647       66,688,647
Increase (Decrease) in Stockholders' Equity          
Net loss         $ (86,990)
Balance at end of period at Sep. 30, 2023 $ 1 926,766 (1,129) (769,305) $ 156,333
Balance at end of period (in shares) at Sep. 30, 2023 70,818,954       70,818,954
Balance at beginning of period at Mar. 31, 2023 $ 1 887,638 (354) (710,475) $ 176,810
Balance at beginning of period (in shares) at Mar. 31, 2023 67,206,025        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units   30     30
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) 163,677        
Issuance of common stock under at-the-market sales agreement, net of offering costs   26,714     26,714
Issuance of common stock under at-the-market sales agreement, net of offering costs (in shares) 3,400,000        
Unrealized gain (loss) on marketable securities     (757)   (757)
Stock-based compensation expense   6,522     6,522
Net loss       (29,569) (29,569)
Balance at end of period at Jun. 30, 2023 $ 1 920,904 (1,111) (740,044) 179,750
Balance at end of period (in shares) at Jun. 30, 2023 70,769,702        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units   (86)     (86)
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) 49,252        
Unrealized gain (loss) on marketable securities     (18)   (18)
Stock-based compensation expense   5,948     5,948
Net loss       (29,261) (29,261)
Balance at end of period at Sep. 30, 2023 $ 1 $ 926,766 $ (1,129) $ (769,305) $ 156,333
Balance at end of period (in shares) at Sep. 30, 2023 70,818,954       70,818,954